Yep, efficacy will definitely bring world-wide attention to this humble little stock that right now is quietly hidden away in the world's most remote city, and with it a MC that will be many, many multiples of where it sits currently.
Triple this you say Zac? I would suggest waaay beyond triple if efficacy is shown myself.
As the board of AGN put it, Proving the neuroprotective ability of ARG-007 will be a significant derisking milestone for the Company and opportunity to place Argenica at the forefront of neuroprotective clinical validation.
Ann: First Patient Dosed in Phase 2 Stroke Trial of ARG-007, page-16
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
77.5¢ |
Change
0.035(4.73%) |
Mkt cap ! $95.18M | |||
| Open | High | Low | Value | Volume |
| 75.0¢ | 80.0¢ | 71.0¢ | $351.6K | 466.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 49477 | 76.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 83.0¢ | 3012 | 1 |
View Market Depth
| Last trade - 16.10pm 29/05/2024 (20 minute delay) ? |
|
|||||
|
Last
77.5¢ |
Change
0.035 ( 4.73 %) |
||||
| Open | High | Low | Volume | ||
| 73.0¢ | 79.5¢ | 71.0¢ | 125397 | ||
| Last updated 15.55pm 29/05/2024 ? | |||||
| AGN (ASX) Chart |